A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
|Articles|April 5, 2022
Daily OTC Pearl: Lidocaine Pain Relief
Author(s)Saro Arakelians, PharmD
Lidocaine is a local anesthetic that offers temporary relief of pain and itching.
Advertisement
OTC/Lifestyle Pearl of the Day: Lidocaine Pain Relief
Indication: Lidocaine is alocal anesthetic that offerstemporary relief of pain and itching.It prevents pain by blocking the signals at the nerve endings in the skin.
Insight:
- Active ingredient: Lidocaine HCI 4%
- Inactive ingredients: Acrylates/C10-30 alkyl acrylate crosspolymer, aloe barbadensis leaf juice, aminomethyl propanol, C30-45 alkyl cetearyl dimethicone crosspolymer, caprylyl methicone, cetearyl alcohol, ceteth-20 phosphate, dicetyl phosphate, dimethicone, disodium EDTA, ethylhexylglycerin, glyceryl stearate, methylparaben, SD alcohol 40, steareth-21, water.
- Directions: In adults and children 2 years of age and older, apply to affected area no more than 3 to 4 times daily. For children under 2 years of age, consult a physician.
- Warnings: For external use only. When using this product, use only as directed.
- Avoid contact with eyes.
- Do not use in large quantities, particularly over raw surfaces or blistered areas.
- Stop use and ask a physician if condition worsens, if symptoms persist for more than 7 days, or clear up and occur again within a few days.
- Keep out of reach of children.
- If swallowed, get medical help or contact a poison control center immediately.
Source:
Advertisement
Related to this article
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
5